Actinium Pharmaceuticals, Inc. — 2014 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2014. Although the request identifies 2014 Q4, this filing reports annual results; it does not provide a clear standalone fourth-quarter financial breakdown. The company is a clinical-stage biopharmaceutical developer with no product sales.
Business context and development outlook
- Lead candidates are Actimab-A, an Ac-225 antibody construct in a Phase 1/2 AML trial, and Iomab-B, an I-131 antibody construct being prepared for a pivotal Phase 3 trial in relapsed or refractory AML patients age 55 and older.
- The FDA had provided feedback that key features of the proposed Iomab-B Phase 3 design were generally acceptable, but the company had no Special Protocol Assessment. The proposed study was about 150 patients; the company anticipated seeking to start the trial in 2015 and estimated direct trial costs of approximately $25–30 million, with completion anticipated in 2017.
- Actimab-A received FDA orphan-drug designation in November 2014. The company was considering, but had not reported obtaining, breakthrough-therapy designation for either lead candidate.
Financial performance and liquidity
| Metric | FY 2014 | FY 2013 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $12.27 million | $3.11 million |
| General and administrative expense | $10.18 million | $3.48 million |
| Total operating expenses | $22.48 million | $6.59 million |
| Net loss | $24.69 million | $10.77 million |
| Net loss per share, basic and diluted | $0.90 | $0.47 |
| Cash used in operating activities | $14.35 million | $6.29 million |
| Cash and cash equivalents at year-end | $6.71 million | $5.53 million |
- Net loss widened by approximately $13.9 million, chiefly as development spending and stock-based compensation increased. R&D growth was driven largely by Iomab-B manufacturing and Actimab-A trial costs; G&A growth reflected higher stock compensation, salaries, and professional fees.
- Operating cash outflow increased by approximately $8.1 million year over year. Financing activities provided $15.71 million in 2014, primarily from stock issuance.
- At December 31, 2014, current assets were $7.41 million and current liabilities were $9.49 million, implying a working-capital deficit of about $2.08 million. Total assets were $7.57 million; total liabilities were $9.49 million; stockholders’ deficit was $1.92 million.
- Reported notes payable were $283,552, primarily insurance-premium financing. Separately, derivative warrant liabilities were $6.71 million; these are not conventional borrowings. The filing reports no material off-balance-sheet arrangements.
- Margins are not meaningful because the company had no revenue. Accumulated deficit reached $91.2 million.
- After year-end, the company raised approximately $18.5 million net in a February 2015 stock-and-warrant offering. Management stated it expected available cash to fund operations for the next 12 months and estimated approximately $9.6 million was needed for the coming year; these are management estimates, not a guarantee of runway.
Material changes, risks, and unusual items
- R&D expense rose from $3.1 million to $12.3 million and G&A from $3.5 million to $10.2 million. Stock-based compensation totaled $6.28 million in 2014, versus $0.66 million in 2013.
- The $2.21 million 2014 loss from changes in derivative-liability fair value was non-cash and tied to warrants with anti-dilution provisions; the comparable 2013 loss was $4.18 million. Warrant valuation depends in part on management assumptions.
- Clinical and regulatory outcomes remain uncertain. The filing reports prolonged bone-marrow suppression at the highest Actimab-A dose levels tested, prompting dose reductions. The company cautions that trial results may not predict later-stage outcomes and that FDA approval is not assured.
- Funding needs are substantial: the company estimated approximately $25–30 million to complete the Iomab-B Phase 3 trial and about $7 million in direct costs to complete both parts of the ongoing Actimab-A Phase 1/2 trial. Failure to obtain financing or a suitable partner could delay, reduce, or halt programs and could dilute shareholders.
- Ac-225 supply depends on an Oak Ridge National Laboratory contract scheduled to expire at the end of 2015 and requiring renewal. The company also disclosed that commercial-scale cyclotron supply would require further access and investment.
- Iomab-B has no patent protection; the company relies on trade secrets and potential regulatory exclusivity. Actimab-A depends on licensed intellectual property and carries contractual milestones and royalties, including a 12% AbbVie royalty on licensed-product net sales and a 2% MSKCC royalty on applicable licensed products.
- Significant commitments include a $3.3 million Iomab-B antibody manufacturing agreement with approximately $2.2 million remaining at year-end, plus clinical, research, licensing, and royalty obligations. The company reported owing MSKCC about $189,000 in year-end fees and research support in one disclosure; another note describes a larger accumulated amount under a separate 2011–2014 letter agreement, so the precise total obligations merit review.
- The company reported that management and its auditor considered internal control over financial reporting effective at year-end; the financial statement audit opinion was unqualified. Management said previously identified control weaknesses had been remediated during 2014.
Important facts for investors to verify
- Whether the February 2015 financing, subsequent share issuances, and outstanding warrants and options provide adequate funding without excessive dilution. At year-end 2014, 3.01 million options and 7.63 million warrants were outstanding; the February offering added warrants to buy 3.33 million shares.
- Current status, enrollment, safety, and milestones for both lead trials, including FDA requirements and the planned Iomab-B Phase 3 start, design, and financing.
- Renewal and adequacy of Ac-225 supply after the ORNL contract’s stated 2015 expiration, and the feasibility and cost of alternative production.
- Reconciliation of MSKCC amounts payable and the company’s full remaining contractual commitments, including manufacturing and trial costs.
- Potential impact of stock-based compensation, warrant-liability remeasurement, and future equity financing on reported losses, cash needs, and shareholder dilution.